Merck Sharp & Dohme LLC
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically or cytologically confirmed advanced/metastatic solid tumor; including head and neck squamous cell carcinoma, cervical squamous cell carcinoma, esophageal squamous cell carcinoma, breast cancer (triple negative breast cancer, Estrogen Receptor \[ER\]/progesterone receptor +, human epidermal growth factor receptor 2 negative \[HER2-\]), endometrial, and bladder cancer by pathology report and have previously failed standard treatment, lack standard treatment options, or are intoler…
30 µg via intravenous (IV) infusion
100 µg via intravenous (IV) infusion
300 µg via intravenous (IV) infusion
1 mg via intravenous (IV) infusion
3 mg via intravenous (IV) infusion
10 mg via intravenous (IV) infusion
30 mg via intravenous (IV) infusion
70 mg via intravenous (IV) infusion
IV Infusion